Video
Expert Discusses Challenges, Risks of Ibrutinib as Chronic Lymphocytic Leukemia Treatment
Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discusses her ASH 2021 presentation and addresses some of the challenges and risk of ibrutinib as treatment for CLL.
In a Pharmacy Times® interview, Lindsey Roeker, MD, assistant attending L1 at Memorial Sloan Kettering Cancer Center, discussed her ASH 2021 presentation, A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.
She addressed some of the challenges and risk of ibrutinib treatment for CLL.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
